(NASDAQ: VALN) Valneva Se's forecast annual revenue growth rate of 20.64% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 102.02%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.67%.
Valneva Se's revenue in 2025 is $206,796,551.On average, 7 Wall Street analysts forecast VALN's revenue for 2025 to be $28,939,181,396, with the lowest VALN revenue forecast at $26,337,578,220, and the highest VALN revenue forecast at $31,716,173,551. On average, 7 Wall Street analysts forecast VALN's revenue for 2026 to be $32,563,886,945, with the lowest VALN revenue forecast at $27,612,396,256, and the highest VALN revenue forecast at $40,105,613,006.
In 2027, VALN is forecast to generate $64,283,308,440 in revenue, with the lowest revenue forecast at $51,928,129,312 and the highest revenue forecast at $72,844,888,929.